Article
Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025
2026-08-17
Abstract excerpt
<h4>Background: </h4> /Objectives. Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infection in infants. Panama introduced the bivalent prefusion F vaccine (RSVpreF) for administration between 32.0 and 36.6 weeks of gestation in July 2025. In this tropical setting, respiratory viruses are detected throughout the year, with RSV activity increasing during the rainy season. We chara...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0d3db74f-9814-5aa8-9a73-72f6aeb241d2
- DOI
- 10.20944/preprints202608.1049.v1
